Shmt2: A Stat3 Signaling New Player in Prostate Cancer Energy Metabolism
Ilaria Marrocco1, Fabio Altieri2, Elisabetta Rubini3
1Department of Biochemical Sciences "A. Rossi Fanelli" and Istituto Pasteur-Fondazione Cenci Bolognetti, Sapienza University, P.le A. Moro 5, 00185 Rome, Italy. ilaria.marrocco@weizmann.ac.il.
Abstract:
Prostate cancer (PCa) is a multifactorial disease characterized by the aberrant activity of different regulatory pathways. STAT3 protein mediates some of these pathways and its activation is implicated in the modulation of several metabolic enzymes. A bioinformatic analysis indicated a STAT3 binding site in the upstream region of SHMT2 gene. We demonstrated that in LNCaP, PCa cells' SHMT2 expression is upregulated by the JAK2/STAT3 canonical pathway upon IL-6 stimulation. Activation of SHTM2 leads to a decrease in serine levels, pushing PKM2 towards the nuclear compartment where it can activate STAT3 in a non-canonical fashion that in turn promotes a transient shift toward anaerobic metabolism. These results were also confirmed on FFPE prostate tissue sections at different Gleason scores. STAT3/SHMT2/PKM2 loop in LNCaP cells can modulate a metabolic shift in response to inflammation at early stages of cancer progression, whereas a non-canonical STAT3 activation involving the STAT3/HIF-1α/PKM2 loop is responsible for the maintenance of Warburg effect distinctive of more aggressive PCa cells. Chronic inflammation might thus prime the transition of PCa cells towards more advanced stages, and SHMT2 could represent a missing factor to further understand the molecular mechanisms responsible for the transition of prostate cancer towards a more aggressive phenotype.
Insights
This study reveals a STAT3 signaling loop involving SHMT2 and PKM2 that drives metabolic shifts in prostate cancer (PCa). This pathway contributes to cancer progression and may link inflammation to more aggressive phenotypes.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Metabolism
Background:
- Prostate cancer (PCa) involves complex regulatory pathways, with STAT3 protein influencing metabolic enzymes.
- STAT3 activation is linked to aberrant metabolic activity in cancer cells, including the Warburg effect.
Purpose of the Study:
- To investigate the role of the STAT3 pathway and its interaction with SHMT2 in prostate cancer progression.
- To elucidate the molecular mechanisms linking inflammation, metabolic reprogramming, and PCa aggressiveness.
Main Methods:
- Bioinformatic analysis to identify STAT3 binding sites on the SHMT2 gene.
- In vitro studies using LNCaP cells (PCa cell line) to examine JAK2/STAT3 pathway activation and SHMT2 expression.
- Analysis of FFPE prostate tissue sections from patients with varying Gleason scores.
Main Results:
- IL-6 stimulation upregulated SHMT2 expression via the JAK2/STAT3 pathway in LNCaP cells.
- SHMT2 activation decreased serine levels, promoting nuclear PKM2 translocation and non-canonical STAT3 activation, leading to a shift towards anaerobic metabolism.
- A STAT3/SHMT2/PKM2 loop was identified in early-stage PCa, while a STAT3/HIF-1α/PKM2 loop maintained the Warburg effect in aggressive PCa.
Conclusions:
- The STAT3/SHMT2/PKM2 loop mediates metabolic shifts in response to inflammation during early PCa.
- Chronic inflammation may promote PCa progression through STAT3-mediated metabolic reprogramming.
- SHMT2 is a potential key factor in understanding the transition to aggressive prostate cancer phenotypes.
Related Concept Videos
13:18How to Study Basement Membrane Stiffness as a Biophysical Trigger in Prostate Cancer and Other Age-related Pathologies or Metabolic Diseases
07:16Isolation of Cancer Stem Cells From Human Prostate Cancer Samples
09:43Isolation, Culture, and Characterization of Prostate Cancer-Associated Fibroblasts
05:07Intra-prostatic Injection of Cancer Cells: A Technique to Deliver Cancer Cells for Establishing Orthotopic Prostate Cancer Mouse Model
11:07Focal Laser Ablation of Prostate Cancer: An Office Procedure
06:48An Orthotopic Murine Model of Human Prostate Cancer Metastasis


